OmicEra Diagnostics has been selected for EIT Health's Gold Track program. The leading mentoring initiative aims to support the Planegg-based start-up's success in the global market. The company is developing a proteome analysis platform for medical diagnostics.
OmicEra Diagnostics from Planegg is developing a new analysis platform for proteome analytics in medical diagnostics. At the end of October, the start-up was selected for EIT Health's Gold Track program and is now receiving various coaching sessions from experienced mentors for the young company's entry into the global market.
OmicEra Diagnostics was already able to convince this year at the 11th "Start?Zuschuss!" competition of the Bavarian Ministry of Economic Affairs, which is specifically aimed at technology-oriented start-ups in the field of digitalization.
Sophia Doll, Co-Founder of OmicEra, is very pleased:
"In a highly competitive process led by an expert panel of successful entrepreneurs and top industry executives, we successfully demonstrated our ability to innovate and scale. EIT Health will now help us achieve our business goals."
EIT Health Gold Track program
With the goal of creating international success stories of European biotech companies to strengthen the industry, the Gold Track program matches promising companies with high-profile advisors from the life sciences sector.
The Gold Track program builds on personal relationships between mentors and mentees. Through individual 1:1 coaching sessions, the program helps young companies grow their network and develop new business and investment opportunities in a short period of time. Together, they work to deepen their strategy and its operational implementation.